Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Late-Stage Pipeline

25%

4 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

12 recruiting

Enrollment Performance

Analytics

Phase 1

11(68.8%)

Phase 3

4(25.0%)

Phase 2

1(6.3%)

16Total

Phase 1(11)

Phase 3(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT07365995Phase 3Recruiting

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Role: collaborator

NCT06340568Phase 3Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Role: collaborator

NCT06827236Phase 1Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Role: collaborator

NCT06892548Phase 1Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Role: collaborator

NCT07141706Phase 1Recruiting

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

Role: lead

NCT05785741Phase 1Recruiting

A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors

Role: lead

NCT06554795Phase 1Recruiting

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

Role: lead

NCT06018337Phase 3Active Not Recruiting

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)